Pembrolizumab in recurrent advanced cervical squamous carcinoma
| العنوان: | Pembrolizumab in recurrent advanced cervical squamous carcinoma |
|---|---|
| المؤلفون: | Pablo Martinez, Josep María Del Campo |
| المصدر: | Immunotherapy. 9:467-470 |
| بيانات النشر: | Future Medicine Ltd, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Adult, Oncology, medicine.medical_specialty, medicine.medical_treatment, Immune checkpoint inhibitors, Programmed Cell Death 1 Receptor, Immunology, Uterine Cervical Neoplasms, Antineoplastic Agents, Cervix Uteri, Pembrolizumab, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Cervical carcinoma, medicine, Humans, Immunology and Allergy, 030212 general & internal medicine, Cervix, Peritoneal Neoplasms, Neoplasm Staging, Chemotherapy, business.industry, Remission Induction, Treatment options, Cancer, medicine.disease, Tumor Burden, Squamous carcinoma, medicine.anatomical_structure, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Female, Immunotherapy, Neoplasm Recurrence, Local, business |
| الوصف: | No definitive cure is known for recurrent, persistent or metastatic cervical carcinoma. Chemotherapy remains the standard of care, although available options are scarce and do not provide satisfactory results. Immune checkpoint inhibitors have shown a strong and prolonged response in several types of cancer, although only in a subset of patients. Defining the profile of the patients likely to benefit from such treatment is a subject of active research. Here, we present a case of a heavily pretreated patient with recurrent advanced squamous cell carcinoma of the cervix who had exhausted all available treatment options and showed a striking response to the immune checkpoint inhibitor pembrolizumab. |
| تدمد: | 1750-7448 1750-743X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28707cdd297a6e7276ec734648ac0cfTest https://doi.org/10.2217/imt-2016-0119Test |
| رقم الانضمام: | edsair.doi.dedup.....f28707cdd297a6e7276ec734648ac0cf |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....f28707cdd297a6e7276ec734648ac0cf 833 3 unknown 832.608703613281 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f28707cdd297a6e7276ec734648ac0cf&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Pembrolizumab in recurrent advanced cervical squamous carcinoma
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Pablo+Martinez%22">Pablo Martinez</searchLink><br /><searchLink fieldCode="AR" term="%22Josep+María+Del+Campo%22">Josep María Del Campo</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>Immunotherapy</i>. 9:467-470 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Future Medicine Ltd, 2017. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2017 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Oncology%22">Oncology</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Ftreatment%22">medicine.medical_treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Immune+checkpoint+inhibitors%22">Immune checkpoint inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22Programmed+Cell+Death+1+Receptor%22">Programmed Cell Death 1 Receptor</searchLink><br /><searchLink fieldCode="DE" term="%22Immunology%22">Immunology</searchLink><br /><searchLink fieldCode="DE" term="%22Uterine+Cervical+Neoplasms%22">Uterine Cervical Neoplasms</searchLink><br /><searchLink fieldCode="DE" term="%22Antineoplastic+Agents%22">Antineoplastic Agents</searchLink><br /><searchLink fieldCode="DE" term="%22Cervix+Uteri%22">Cervix Uteri</searchLink><br /><searchLink fieldCode="DE" term="%22Pembrolizumab%22">Pembrolizumab</searchLink><br /><searchLink fieldCode="DE" term="%22Antibodies%2C+Monoclonal%2C+Humanized%22">Antibodies, Monoclonal, Humanized</searchLink><br /><searchLink fieldCode="DE" term="%22B7-H1+Antigen%22">B7-H1 Antigen</searchLink><br /><searchLink fieldCode="DE" term="%22Disease-Free+Survival%22">Disease-Free Survival</searchLink><br /><searchLink fieldCode="DE" term="%2203+medical+and+health+sciences%22">03 medical and health sciences</searchLink><br /><searchLink fieldCode="DE" term="%220302+clinical+medicine%22">0302 clinical medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Cervical+carcinoma%22">Cervical carcinoma</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Immunology+and+Allergy%22">Immunology and Allergy</searchLink><br /><searchLink fieldCode="DE" term="%22030212+general+%26+internal+medicine%22">030212 general & internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Cervix%22">Cervix</searchLink><br /><searchLink fieldCode="DE" term="%22Peritoneal+Neoplasms%22">Peritoneal Neoplasms</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasm+Staging%22">Neoplasm Staging</searchLink><br /><searchLink fieldCode="DE" term="%22Chemotherapy%22">Chemotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Remission+Induction%22">Remission Induction</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+options%22">Treatment options</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer%22">Cancer</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Tumor+Burden%22">Tumor Burden</searchLink><br /><searchLink fieldCode="DE" term="%22Squamous+carcinoma%22">Squamous carcinoma</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Eanatomical%5Fstructure%22">medicine.anatomical_structure</searchLink><br /><searchLink fieldCode="DE" term="%22Lymphatic+Metastasis%22">Lymphatic Metastasis</searchLink><br /><searchLink fieldCode="DE" term="%22030220+oncology+%26+carcinogenesis%22">030220 oncology & carcinogenesis</searchLink><br /><searchLink fieldCode="DE" term="%22Carcinoma%2C+Squamous+Cell%22">Carcinoma, Squamous Cell</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Immunotherapy%22">Immunotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasm+Recurrence%2C+Local%22">Neoplasm Recurrence, Local</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => No definitive cure is known for recurrent, persistent or metastatic cervical carcinoma. Chemotherapy remains the standard of care, although available options are scarce and do not provide satisfactory results. Immune checkpoint inhibitors have shown a strong and prolonged response in several types of cancer, although only in a subset of patients. Defining the profile of the patients likely to benefit from such treatment is a subject of active research. Here, we present a case of a heavily pretreated patient with recurrent advanced squamous cell carcinoma of the cervix who had exhausted all available treatment options and showed a striking response to the immune checkpoint inhibitor pembrolizumab. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1750-7448<br />1750-743X ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28707cdd297a6e7276ec734648ac0cf" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28707cdd297a6e7276ec734648ac0cf</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.2217/imt-2016-0119" linkWindow="_blank">https://doi.org/10.2217/imt-2016-0119</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....f28707cdd297a6e7276ec734648ac0cf ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 4
[StartPage] => 467
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Adult
[Type] => general
)
[1] => Array
(
[SubjectFull] => Oncology
[Type] => general
)
[2] => Array
(
[SubjectFull] => medicine.medical_specialty
[Type] => general
)
[3] => Array
(
[SubjectFull] => medicine.medical_treatment
[Type] => general
)
[4] => Array
(
[SubjectFull] => Immune checkpoint inhibitors
[Type] => general
)
[5] => Array
(
[SubjectFull] => Programmed Cell Death 1 Receptor
[Type] => general
)
[6] => Array
(
[SubjectFull] => Immunology
[Type] => general
)
[7] => Array
(
[SubjectFull] => Uterine Cervical Neoplasms
[Type] => general
)
[8] => Array
(
[SubjectFull] => Antineoplastic Agents
[Type] => general
)
[9] => Array
(
[SubjectFull] => Cervix Uteri
[Type] => general
)
[10] => Array
(
[SubjectFull] => Pembrolizumab
[Type] => general
)
[11] => Array
(
[SubjectFull] => Antibodies, Monoclonal, Humanized
[Type] => general
)
[12] => Array
(
[SubjectFull] => B7-H1 Antigen
[Type] => general
)
[13] => Array
(
[SubjectFull] => Disease-Free Survival
[Type] => general
)
[14] => Array
(
[SubjectFull] => 03 medical and health sciences
[Type] => general
)
[15] => Array
(
[SubjectFull] => 0302 clinical medicine
[Type] => general
)
[16] => Array
(
[SubjectFull] => Internal medicine
[Type] => general
)
[17] => Array
(
[SubjectFull] => Cervical carcinoma
[Type] => general
)
[18] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[19] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[20] => Array
(
[SubjectFull] => Immunology and Allergy
[Type] => general
)
[21] => Array
(
[SubjectFull] => 030212 general & internal medicine
[Type] => general
)
[22] => Array
(
[SubjectFull] => Cervix
[Type] => general
)
[23] => Array
(
[SubjectFull] => Peritoneal Neoplasms
[Type] => general
)
[24] => Array
(
[SubjectFull] => Neoplasm Staging
[Type] => general
)
[25] => Array
(
[SubjectFull] => Chemotherapy
[Type] => general
)
[26] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[27] => Array
(
[SubjectFull] => Remission Induction
[Type] => general
)
[28] => Array
(
[SubjectFull] => Treatment options
[Type] => general
)
[29] => Array
(
[SubjectFull] => Cancer
[Type] => general
)
[30] => Array
(
[SubjectFull] => medicine.disease
[Type] => general
)
[31] => Array
(
[SubjectFull] => Tumor Burden
[Type] => general
)
[32] => Array
(
[SubjectFull] => Squamous carcinoma
[Type] => general
)
[33] => Array
(
[SubjectFull] => medicine.anatomical_structure
[Type] => general
)
[34] => Array
(
[SubjectFull] => Lymphatic Metastasis
[Type] => general
)
[35] => Array
(
[SubjectFull] => 030220 oncology & carcinogenesis
[Type] => general
)
[36] => Array
(
[SubjectFull] => Carcinoma, Squamous Cell
[Type] => general
)
[37] => Array
(
[SubjectFull] => Female
[Type] => general
)
[38] => Array
(
[SubjectFull] => Immunotherapy
[Type] => general
)
[39] => Array
(
[SubjectFull] => Neoplasm Recurrence, Local
[Type] => general
)
[40] => Array
(
[SubjectFull] => business
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Pembrolizumab in recurrent advanced cervical squamous carcinoma
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pablo Martinez
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Josep María Del Campo
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 05
[Type] => published
[Y] => 2017
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 17507448
)
[1] => Array
(
[Type] => issn-print
[Value] => 1750743X
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsair
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 9
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Immunotherapy
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |